NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

Sees FY25 operating expenses $92M-$95M. Management also outlined its long-range plan of becoming the recognized ...

NeuroPace provided initial financial guidance targets for 2025: Revenue of $92 million – $96 million, representing growth of 15.5% – 20.5% versus the midpoint of the expected 2024 revenue range of $79 ...

Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven - MOUNTAIN VIEW, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company ...

Fintepla (fenfluramine) is a prescription drug used to treat seizures from certain epilepsy conditions. Fintepla can cause side effects that range from mild to serious. Examples include diarrhea ...

NeuroPace, Inc., a medical device company specializing in epilepsy treatment, announced its 2025 financial guidance, estimating revenues between $92 million and $96 million, which reflects a ...

which is idiopathic, from secondary hyperhidrosis, which can be due to a variety of medical conditions (see Table 1). Secondary hyperhidrosis can have a focal or generalized clinical presentation ...

3,4 W.S., a 56-year-old Negro hospital orderly, was admitted to Philadelphia General Hospital on April 13, 1958, because of a generalized ... osteoblastic metastases. Seizures were controlled ...

The child was prescribed the drug carbamazepine following her diagnosis, per the ABC, but the treatment was stopped after it was suspected the medication was triggering seizures. The woman still ...

Expert Rev Pharmacoeconomics Outcomes Res. 2009;9(1):49-64. Patients with insomnia often seek professional help because of their perceived daytime symptoms rather than the amount or quality of ...